The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)
- Conditions
- Resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000027441
- Lead Sponsor
- Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Not provided
(1)Patients who could not resected curatively.(2)Patients with active double cancer. (3)Patients with serious drug hypersensitivity or with a history of drug allergy.(4)Patients with serious complications.(5)Patients with jaundice,cirrhosis or with suspected cirrhosis of the liver.(6)There is a history of chronic hepatitis B, and in the present study drug has already been ingested.(7)Patients with active infection.(8)Women who have a possibility of or in the pregnancy,who hope to become pregnant,or who are breast-feeding. Men who wish to become pregnant partner.(9)Patients with severe mental disorder.(10)Other patients whom the physician decided to be unsuitable for safely carrying out the present study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method efficacy